232 results about "Premature ovarian failure" patented technology

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention discloses a health-care product for preventing and treating premature ovarian failure and a preparation method thereof. The health-care product comprises medlar, glossy privet fruit, prepared rehmannia, epimedium, malaytea scurfpea fruit, Chinese dodder seeds, raspberry, peanut, Chinese date and soy. The preparation method comprises the following steps of: weighing raw materials according to a weight proportion; soaking with ethanol; performing reflux extraction; filtering, and keeping the filtrate for later use; performing reflux extraction on the residue twice with ethanol; re-filtering, and keeping the filtrate for later use; combining the filtrate, and concentrating the filtrate until ethanol odor does not exist so as to obtain ethanol extract; and decocting the residue twice, filtering to obtain water extract, and combining the ethanol extract and the water extract to obtain the health-care product. The health-care product has excellent effect of improving the ovary function, and has the effects of improving the ovary function, achieving the effect of estrogen, improving the symptoms of weight loss, desudation and the like caused by ovarian failure, regulating the response of the ovary to gonadotropin, promoting follicular development and the like for 40-year-old women particularly.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention provides a Chinese medicinal composition for treating premature ovarian failure, which is prepared from the following Chinese medicinal raw materials in part by weight: 2 to 6 parts of radix rehmanniae praeparata, 2 to 6 parts of common macrocarpium fruit, 2 to 6 parts of Chinese angelica, 2 to 6 parts of white paeony root, 2 to 6 parts of folium epimedii and 1 to 3 parts of root of red-rooted salvia. The invention also provides a preparation method of the Chinese medicinal composition, and adopts the technical scheme that the Chinese medicinal composition can be prepared into tablets, capsules, pills, granules, soft capsules and oral administration liquid preparations.

The invention provides a vaginal tightening, cleaning and anti-inflammation traditional Chinese medicine composition for women. The composition is prepared from, by weight, 25-70 parts of common cruculigo rhizome extracts, 20-45 parts of radix angelica sinensis, 15-45 parts of fructus cnidii, 20-50 parts of pericarpium granati, 5-40 parts of saussurea involucrata, 3-15 parts of radix sophora flavescens, 5-15 parts of cortex phellodendri, 5-40 parts of fructus kochiae, 5-10 parts of radix stemonae, 5-55 parts of epimedium, 5-38 parts of cistanche deserticola, 5-10 parts of chlorhexidine acetate, 2-20 parts of ginsenosides, 10-25 parts of tenodera aridifolia stoll and 10-22 parts of ginkgo. The composition has the effects of repairing vaginal mucosae and healing cervical injuries and the functions of repairing elasticity and nourishing and regenerating the pelvic floor muscles and ligaments around the vagina, and can be used in private parts of women and easily absorbed by the skin and the mucosae. The composition can be used for recovering the vaginal tightness and elasticity, and vaginal relaxation, flatus vaginalis and urine leakage phenomena caused by various reasons such as parturition, abortion, frequent sexual activities, aging and premature ovarian failure are alleviated. The traditional Chinese medicine composition is mainly used for contracting and tightening the vaginae of the women and has the function of uterus warming, detoxification, sterilization, anti-inflammation, vagina nourishing and protecting and the like.

The invention discloses a Chinese herba preparation for treating the premature ovarian failure. The Chinese herba preparation is made of prepared rehmannia root, fried Chinese yam, teasel root, vinegar-processed radix bupleuri, rhizoma cyperi, curcuma aromatica, loranthus parasiticus, eucommia ulmoides, semen cuscutae, flatstem milkvetch seed, barbary wolfberry fruit, achyranthes root, dogwood, angelica sinensis, ligusticum wallichii, radix paeoniae alba, fried bighead atractylodes rhizome, codonopsis pilosula, semen plantaginis, glossy privet fruit, cornu cervi degelatinatum, colla corii asini, trigone and curcuma zedoary according to a certain weight ratio. The Chinese herba preparation has the effects of nourishing yin and blood, boosting essence, filling marrow, supplementing qi, promoting the production of body fluid, promoting qi circulation and relieving depression; the Chinese herba preparation has the good effect on improving the ovarian function, the physique of a patient can be strengthened, the Chinese herba preparation further has the advantages of being low in price and free of toxic and side effects, and therefore the effect of treating the premature ovarian failure is achieved.

The invention discloses the application of astragalin in preparation of anti-ovarian-senescence medicaments. Astragalin can treat various ovarian failure diseases, and has a remarkable effect on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or climacteric syndrome and the like. According to the invention, astragalin is prepared into oral medicaments, percutaneous medicaments or parenteral medicaments for treating ovarian failure diseases.

The invention relates to a method for treating premature ovarian failure by virtue of placenta mesenchymal stem cells and a cell preparation and particularly relates to the cell preparation on one hand. The cell preparation is cell suspension prepared by mixing mesenchymal stem cells such as placenta mesenchymal stem cells into a 0.9% sodium chloride solution and is particularly prepared by the steps of transferring mesenchymal stem cells obtained through cell passage into a centrifuge tube, carrying out centrifuging to remove supernatant, adding the 0.9% sodium chloride solution, and carryingout resuspension, so as to obtain the cell preparation. The mesenchymal stem cells are prepared by the steps of processing placental lobules, carrying out digestion and termination on mixed enzyme, collecting primary cells, carrying out cryopreservation on the primary cells, carrying out thawing, passage, detection and cryopreservation on the cells, and relating with a database. The cell preparation prepared by virtue of the method presents excellent biological effect in the treatment of the premature ovarian failure.

The invention relates to a medicinal liquor capable of maintaining beauty and keeping young and a preparation method thereof. The medicinal liquor is prepared by soaking the following raw materials by weight in pure rice wine with a volume of 1900 to 2100 mL: 30 to 50 grams of China rose flower, 30 to 50 grams of rose flower, 20 to 40 grams of peach flower, 30 to 50 grams of ginseng flower, 30 to 50 grams of lotus, 30 to 50 grams of lily, 10 to 30 grams of safflower, 30 to 50 grams of globe amaranth, 30 to 50 grams of red sage root, 40 to 60 grams of radices hemerocallis, 20 to 40 grams of Indian kalimeris herb, 40 to 60 grams of rhizoma nardostachyos, 60 to 80 grams of Chinese angelica, 50 to 70 grams of ligusticum wallichii, 40 to 60 grams of white peony root, 40 to 60 grams of radix rehmanniae preparata, 30 to 50 grams of human placenta, 30 to 50 grams of donkey-hide gelatin, 20 to 40 grams of bletilla striata, 20 to 40 parts of radix bupleuri, 40 to 60 grams of red peony root, 40 to 60 grams of cyperus rotundus, 30 to 50 grams of dwarf burnet root, 40 to 60 grams of lucid ganoderma, 40 to 60 grams of korean raspberry root, 60 to 80 grams of epimedium, 30 to 50 grams of semen cuscutae, 30 to 50 grams of artemisia anomala, 30 to 50 grams of wolfberry, 30 to 50 grams of poria cocos, 30 to 50 grams of motherwort, 30 to 50 grams of ligustrum lucidum, 30 to 50 grams of raspberry, 30 to 50 grams of blood vine, 30 to 50 grams of herba lycopi, and 30 to 50 grams of achyranthes root. The medicinal liquor has the advantages of good and rapid effect, has the functions of maintaining beauty, keeping young, eliminating spots in skin, nourish the skin, and modulating the endocrine system, and has a prominent effect on preventing premature ovarian failure. The preparation method is simple and easy to operate.

A medicine for treating various diseases such as women's climacteric syndrome, osteoporosis, mental depression, premature ovarian failure, premenstrual tension syndrome, hyperthyroidism, male and female infertility, hair loss and white hair, and is characterized in that it It is composed of fatty acids in the following weight percent range: hexadecanoic acid 8-32%, hexadecenoic acid 11-35%, octadecenoic acid 13-33%, octadecanoic acid 0.3-2.5%, octadecanoic acid Carbadienoic acid 11-33%, octadecatrienoic acid 3-15%. Compared with other drugs, the drug composition is simple, belongs to the target organ agonist, and has an independent reversible regulation function on the second messenger of the body. It is a medicine with high curative effect, safety and simplification.

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, arthritic condition and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention belongs to the biological engineering and immunology technology fields and specifically relates to a linear epitope minimum motif peptide of human zona pellucida (huZP) protein huZP1 and huZP3, and ZP chimeric peptides. In particular, the invention provides the minimum epitope amino acid sequence on the huZP1 and the huZP3 proteins for detecting ZP antibodies (Leading to the sterility or premature ovarian failure of women) and the 8-peptide sequence containing the epitope minimum motif and of truncated GST188 carrier protein fusion expression. The epitope minimum motif peptide of the huZP1 with immunogenicity can be identified by a rabbit anti-pig ZP antiserum and the 5-epitope minimum peptide motif of huZP3 can be identified by a rabbit antibody human ZP3 antiserum, to prove the value of the epitope minimum motif peptide when used as a single-epitope or multi-epitope peptide contraception antigen or when used as a single-epitope or multi-epitope fusion expression antigen for detecting the ZP antibodies of humans.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention relates to the field of biomedicine, in particular to a menstrual blood source stem cell preparation and a preparation method and application thereof. The menstrual blood source stem cell preparation comprises menstrual blood source stem cells, albumin and normal saline. The experiment indicates that the menstrual blood source stem cell preparation can keep the survival rate of the menstrual blood source stem cells at 99% or above, the cells are uniform in size, and the cells are each in a shuttle shape. After being preserved for 1 month at the temperature of 0-4 DEG C, the cells are still kept in good forms, the abnormal phenomenon such as increase of the size does not appear, the survival rate is still kept at 95% or above, and through surface antigen detection, the menstrual blood source stem cells still keep the characteristics of stem cells, no differentiation is generated, and good activity is achieved. The menstrual blood source stem cell preparation can achieve a good treatment effect when used for treating premature ovarian failure, and after the menstrual blood source stem cell preparation is used for a week, the number of follicles of a mouse is obviously increased.

The invention discloses a marker composition for premature ovarian failure gene detection and a detection kit. The marker composition for premature ovarian failure gene detection is composed of 47 mutation sites of 17 genes including EIF2B2, ERCC6, ESR1, FIGLA, FOXL2, FSHR, HFM1, MCM8, MCM9, MSH5, NOBOX, NR5A1, POF1B, SGO2, STAG3 and SYCE1. According to the application, the marker composition forpremature ovarian failure gene detection is established for the first time, and a detection reagent and a kit are researched and developed according to the marker composition, so that the premature ovarian failure can be accurately, sensitively and specifically detected, therefore, the premature ovarian failure condition and risk can be known and judged more accurately and comprehensively, a reference basis is provided for early diagnosis, risk assessment and prognosis, and a new way and scheme are provided for clinical detection, pathogenesis and genetic research of premature ovarian failure.

The invention relates to a placental mesenchymal stem cell preparation used for treating premature ovarian failure. Particularly, one the one hand, the method that mesenchymal stem cells are separatedfrom placenta tissue and cultured into the mesenchymal stem cells is provided; on the other hand, the cell preparation is provided, wherein the cell preparation is a cell suspension which is preparedin the step that the mesenchymal stem cells, such as placental mesenchymal stem cells, are mixed and suspended into a 0.9% sodium chloride solution. The cell preparation can be used for treating thepremature ovarian failure; particularly, the cell preparation is the placental mesenchymal stem cell preparation. The cell preparation is prepared by using the method including the steps that the mesenchymal stem cells obtained through cell passage are transferred into a centrifuge tube and centrifuged, liquid supernatant is removed, a 0.9% sodium chloride solution is added for resuspension, and the cell preparation is prepared. The cell preparation has an excellent biological effect on treatment of the premature ovarian failure.

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and / or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

The invention relates to the technical field of biological gene detection, and aims to provide an ovarian premature senility related gene whole exon amplification and detection method. The method comprises the following steps: extracting genome DNA from a detection material; using totally 120 primers shown in SEQ ID NO:1-120, carrying out an amplification test on all exons of 9 genes, namely FMR1,FOXL2, FSHR, POF1B, INHA, NOBOX, GDF9, BMP15 and FIGLA, wherein totally 61 PCR reactions in the amplification test and the negative control are carried out synchronously, and the Tm value range of the 120 primers is 57-62 DEG C; detecting an amplification product by adopting agarose electrophoresis and a gel imaging system; and analyzing the sequencing result of the amplification product by usingan automatic sequencer. All exons of 9 genes related to premature ovarian failure are synchronously amplified through optimized PCR amplification specificity, and a detection raw material is providedfor downstream detection. The method is simple and convenient to operate, short in amplification time, high in specificity and good in repeatability. The detected positive rate is greatly improved, and the application prospect is wide.

The invention discloses an application of adipose tissue-derived stromal cells in treating premature ovarian failure, and belongs to the technical field of a biological medicine. Adipose tissue-derived stromal cells and its excreted cell factors, and other components at a certain ratio are applied to form adipose tissue-derived stromal cells; then the adipose tissue-derived stromal cells are prepared to be injection fluid and a drug patch; the injection fluid is injected to the zone where a focus locates through a local target injection method, and then the patch is pasted to a patient's navel; through an electromagnetic impulse generator, a drug is intermittently stimulated, and the secretion of follicle-stimulating hormone is promoted, ovary endometrium can be effectively repaired, the functional ovulation is promoted, and premature ovarian failure is effectively treated. In short, the application has the advantages of being safe and effective, higher in controllability and strong inpracticability.

The invention discloses a stilbene compound, a preparation method and application of the stilbene compound. According to the invention, a substituted coumarin is adopted and used as a raw material, and the raw material is processed by reduction reaction in an organic solvent so as to the stilbene compound. The preparation method of the stilbene compound has the characteristics that the raw material is wide in source and low in cost, the method is simple in operation and mild in condition. The stilbene compound has combinability respect to ER Alpha higher than that respect to ER Beta and is relatively high in selectivity, some compounds show antagonistic effect to the ER Alpha and show partial agonistic action to ER Beta, therefore, the stilbene compound can be applied to preparation of a pharmaceutic preparation for preventing or treating diseases caused by estrogen deficiency or relative lack of estrogen, such as breast cancers, premature ovarian failure, climacteric syndrome, osteoporosis, polycystic ovarian syndrome and infertility.

Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and / or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging.

The invention discloses a traditional Chinese medicine paste preparation capable of tonifying kidney and kidney yin for women and a preparation method of the traditional Chinese medicine paste preparation. The traditional Chinese medicine paste preparation comprises semen cuscutae, ginseng, deer-horn glue, glossy privet fruit, prepared rehmannia roots, wolfberry fruit, rhizoma polygonati, herba epimedii, fried rhizoma atractylodis macrocephalae, angelica sinensis, rhizoma curculiginis, Chinese yam, fried eucommia ulmoides, fructus alpiniae oxyphyllae, cynomorium songaricum, asparagus cochinchinensis, bletilla striata, fried astragalus membranaceus, morinda officinalis, dipsacus roots, radix salviae miltiorrhizae and achyranthes roots; the prepared rehmannia roots, the herba epimedii, radix asparagi, eclipta alba, salted rhizoma anemarrhenae, the dipsacus roots, honey-fried licorice roots and longan aril as the main drugs, the ligusticum wallichii powder, dogwood, paenoiae alba, human placenta and poria cocos as the adjuvants, the traditional Chinese medicine paste preparation nourishes kidney essence, tonifies the spleen, regulating the liver, replenishes qi and enriches blood after being eaten by the women; the traditional Chinese medicine paste preparation helps to treat irregular menstruation, oligomenorrhea, amenorrhea and infertility, improves the low ovarian reserve function and premature ovarian failure, promotes the reproductive health of women, delays ageing, and improves the immunological function; the traditional Chinese medicine paste preparation leads to black hair, removes black spots, helps to grow and moisten the hair, leads to a contented look, and helps to improve the looks.

A Chinese herba preparation for recuperating and curing ovarian hypoplasia of young girls or adult women is hot drink particles or a tea bag or a granular preparation consisting of kudzu roots, hawthorn, soya beans, red beans, black beans, fructus ligustri lucidi, eclipta alba, honeysuckle, Chinese rose, raw liquorice, dried tangerine or orange peels, fructus amomi, folium ginseng, dipsacus roots, eucommia bark, mistletoe, Japanese raspberry roots, winged euonymus twig, radix trichosanthis, pearl powder, yam flour, medicine beans and a packaging material. The Chinese herba preparation is used for preventing, recuperating and curing diseases including ovarian dysplasia or retardation of the young girls, ovarian hypofunction or hyperfunction, too little or too much estrogen secretion and ovarian and uterus dysgenesis of young married women, premature ovarian failure of older women, and barrenness of fertile women due to hypoplasia of ovum of ovarian, is used for moistening skin, retaining youthful looks and eliminating macula, and has the advantages that total effective rate of clinical recuperating and curing reaches 100% and the like.